Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 24, 2025, titled "Zydus receives tentative approval from USFDA for Ibrutinib tablets 140 mg, 280 mg, and 420 mg".

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹963.00

prior close

₹969.40

announcement price

In-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.6%+1.4% vs market

Pharmaceuticals peers, median of 147sector-0.3%+1.2% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty 100 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.3

15m

-0.0

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8-0.6+1.4-0.3+1.2

Next day

+1.1-1.6+2.7-1.4+2.5

+1.6-2.2+3.7-2.0+3.5

+3.4-1.6+4.9-1.0+4.4

+3.3-1.4+4.7-1.0+4.3

+0.1-1.8+1.9-1.6+1.7

-0.4-2.0+1.6-3.5+3.1

15d

+2.4-2.4+4.8-5.0+7.4

+6.2-1.0+7.2-5.3+11.5

+7.4-0.4+7.9-4.4+11.8

+4.4+2.2+2.2-7.6+12.0

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences has received tentative approval from the USFDA to market Ibrutinib tablets in three strengths (140 mg, 280 mg, and 420 mg), a generic version of Imbruvica. Ibrutinib is used to treat blood cancers including Chronic lymphocytic leukaemia (CLL), Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia. The reference brand had annual US sales of USD 2,148.9 million (IQVIA MAT May 2025), making this a large-market opportunity. The product will be manufactured at Zydus's SEZ facility in Ahmedabad. With this, the group has 420 approvals and 484 ANDA filings cumulatively since FY 2003-04.

Likely market impact

Positive for shareholders — the approval targets a blockbuster molecule (over USD 2 billion US market), potentially expanding Zydus's US generics revenue. However, the 'tentative' status means launch may be delayed until patent or exclusivity barriers are resolved, so immediate revenue impact is not guaranteed.